ClinicalTrials.Veeva

Menu

Surgery for Pancreatic Cancer With Oligo-Metastasis (SPaM)

University Hospital Center (CHU) logo

University Hospital Center (CHU)

Status

Completed

Conditions

Pancreatic Surgery
Pancreatic Cancer

Study type

Observational

Funder types

Other

Identifiers

NCT04196816
RECHMPL19_0534

Details and patient eligibility

About

Pancreatic cancer is increasing in incidence and will be the second leading cause of cancer-related deaths in 2030 in the West. Only 10 to 15% of patients are eligible for curative resection with long-term survival rarely exceeding 20% at 5 years. The management of metastatic or recurrent diseases can not, unfortunately, be recommended to date because of limited data available (INCA 2019).

However, recent, low-strength publications have reported encouraging results on the long-term survival of stage IV or recurrent patients.

The aim of the present retrospective cohort study is to analyze results of surgery/destruction of metastatic synchronous or metachronous disease or local recurrence in patients with stage IV pancreatic cancer

Enrollment

200 patients

Sex

All

Ages

18 to 95 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients who had resection or destruction of one or more synchronous or metachronous metastases or local recurrence of pancreatic adenocarcinoma

Details:

  • synchronous lesions, metachrones can be included
  • all distant lesions (hepatic, pulmonary) can be included
  • documented lymph node involvement after analysis of the specimen (hepatic hilum, mesenteric root, retroperitoneal or inter-aortic-cellar) can be included
  • patients with local recurrence who underwent surgical treatment

Exclusion criteria

  • Patient who reject the study protocol

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems